Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab
Time to sustained worsening in the expanded disability status scale as the standard for evaluating the accumulation of disability has been used as a measure of clinical efficacy in many relapsing-remitting multiple sclerosis (RRMS) clinical trials. However, this measurement usually requires a large...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Neurology Research International |
| Online Access: | http://dx.doi.org/10.1155/2011/195831 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564090161070080 |
|---|---|
| author | Y. C. Wang A. Sandrock J. R. Richert L. Meyerson X. Miao |
| author_facet | Y. C. Wang A. Sandrock J. R. Richert L. Meyerson X. Miao |
| author_sort | Y. C. Wang |
| collection | DOAJ |
| description | Time to sustained worsening in the expanded disability status scale as the standard for evaluating the accumulation of disability has been used as a measure of clinical efficacy in many relapsing-remitting multiple sclerosis (RRMS) clinical trials. However, this measurement usually requires a large sample and long-term study to demonstrate the treatment effect. Annualized relapse rate or time to first relapse is also widely used as alternative measurements of clinical efficacy. A formal statistical validation of short-term relapse activity as a surrogate endpoint for long-term sustained progression of disability could potentially permit smaller, shorter, and less expensive clinical trials in RRMS. Four statistical validation/evaluation approaches consistently showed that relapse activity through one year of treatment serves as statistically valid surrogate endpoint for time to sustained progression of disability. The analysis demonstrates that long-term sustained progression of disability can be predicted by short-term relapse measures with 4 consistent validations of statistical approaches, including a formal statistical hypothesis test. This was demonstrated in a large phase III trial of natalizumab and showed that the beneficial clinical effect of natalizumab on sustained progression of disability at 2 years in patients with RRMS can be predicted by the total number of relapses at 1 year. |
| format | Article |
| id | doaj-art-da711bdbac8f470f8918adc475442cfa |
| institution | Kabale University |
| issn | 2090-1852 2090-1860 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neurology Research International |
| spelling | doaj-art-da711bdbac8f470f8918adc475442cfa2025-02-03T01:11:50ZengWileyNeurology Research International2090-18522090-18602011-01-01201110.1155/2011/195831195831Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with NatalizumabY. C. Wang0A. Sandrock1J. R. Richert2L. Meyerson3X. Miao4Department of Biometrics, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USANeurology Clinical Development, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USANeurology Clinical Development, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USADepartment of Biometrics, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USADepartment of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USATime to sustained worsening in the expanded disability status scale as the standard for evaluating the accumulation of disability has been used as a measure of clinical efficacy in many relapsing-remitting multiple sclerosis (RRMS) clinical trials. However, this measurement usually requires a large sample and long-term study to demonstrate the treatment effect. Annualized relapse rate or time to first relapse is also widely used as alternative measurements of clinical efficacy. A formal statistical validation of short-term relapse activity as a surrogate endpoint for long-term sustained progression of disability could potentially permit smaller, shorter, and less expensive clinical trials in RRMS. Four statistical validation/evaluation approaches consistently showed that relapse activity through one year of treatment serves as statistically valid surrogate endpoint for time to sustained progression of disability. The analysis demonstrates that long-term sustained progression of disability can be predicted by short-term relapse measures with 4 consistent validations of statistical approaches, including a formal statistical hypothesis test. This was demonstrated in a large phase III trial of natalizumab and showed that the beneficial clinical effect of natalizumab on sustained progression of disability at 2 years in patients with RRMS can be predicted by the total number of relapses at 1 year.http://dx.doi.org/10.1155/2011/195831 |
| spellingShingle | Y. C. Wang A. Sandrock J. R. Richert L. Meyerson X. Miao Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab Neurology Research International |
| title | Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab |
| title_full | Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab |
| title_fullStr | Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab |
| title_full_unstemmed | Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab |
| title_short | Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab |
| title_sort | short term relapse quantitation as a fully surrogate endpoint for long term sustained progression of disability in rrms patients treated with natalizumab |
| url | http://dx.doi.org/10.1155/2011/195831 |
| work_keys_str_mv | AT ycwang shorttermrelapsequantitationasafullysurrogateendpointforlongtermsustainedprogressionofdisabilityinrrmspatientstreatedwithnatalizumab AT asandrock shorttermrelapsequantitationasafullysurrogateendpointforlongtermsustainedprogressionofdisabilityinrrmspatientstreatedwithnatalizumab AT jrrichert shorttermrelapsequantitationasafullysurrogateendpointforlongtermsustainedprogressionofdisabilityinrrmspatientstreatedwithnatalizumab AT lmeyerson shorttermrelapsequantitationasafullysurrogateendpointforlongtermsustainedprogressionofdisabilityinrrmspatientstreatedwithnatalizumab AT xmiao shorttermrelapsequantitationasafullysurrogateendpointforlongtermsustainedprogressionofdisabilityinrrmspatientstreatedwithnatalizumab |